Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives

NCT02277184 is registered in ClinicalTrials.gov with Julie E. Bauman, MD, MPH as lead sponsor.

NCT NCT02277184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02277184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives
Lead sponsor
Julie E. Bauman, MD, MPH
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2015
Completion date
September 30, 2016
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck